21 reports

Approximately what one-year progression-free survival benefit would a PD-##/ PD-L## inhibitor + CTLA-## inhibitor combination have to demonstrate in first-line NSCLC to drive moderate-to-significant uptake?

  • Antimalarials
  • Chemotherapy
  • Lung Cancer
  • Therapy
  • United States
  • DAPIROLIZUMAB PEGOL - DRUG PROFILE

VUB initiated studies for hepatocellular carcinoma and HIV. ##-Sep-2017 eTheRNA Immunotherapies, announced that it has been awarded a ## million Euros industrial R& D Projects Grant by Flanders Innovation & Entrepreneurship (VLAIO).

  • Antimalarials
  • Immunotherapy
  • Medical Biotechnology
  • World
  • Product Initiative
  • MALARIA - PIPELINE BY AKSHAYA BIO INC, H1 2018
  • MALARIA - PIPELINE BY ABBVIE INC, H1 2018

It develops immunotherapies to treat breast cancer, lung cancer and melanoma, among others.

  • Antimalarials
  • Malaria
  • Research And Development
  • Vaccine
  • Sanaria Inc.
  • Nov 05, 2018: Infinity Pharmaceuticals provides company update and third quarter 2018 financial results
  • May 08, 2018: Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results

His research has explored predictive biomarkers for the use of immunotherapy agents and is he serves as one of the principal investigators of the NCI lung cancer master protocol (Lung MAP).

  • Antimalarials
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Infinity Pharmaceuticals, Inc.
  • 05/28/2018: AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis

Each security is composed of one ordinary share and one warrant.

  • Antimalarials
  • Dementia
  • Therapy
  • Europe
  • AB Science SA

The molecules developed by companies in Phase II and Preclinical stages are ## and ## respectively.

  • Antimalarials
  • United States
  • World
  • Product Initiative
  • Genervon Biopharmaceuticals, LLC
  • MALARIA - PIPELINE BY ABBVIE INC, H2 2017
  • Licensing and Collaboration

It develops immunotherapies to treat breast cancer, lung cancer and melanoma.

  • Antimalarials
  • Immunotherapy
  • Malaria
  • Vaccine
  • Sanaria Inc.

The molecules developed by companies in Phase II and Preclinical stages are ## and ## respectively.

  • Antimalarials
  • United States
  • World
  • Product Initiative
  • Genervon Biopharmaceuticals, LLC

It offers pre-clinical and clinical investigational immunotherapies.

  • Antimalarials
  • Pharmaceutical
  • Therapy
  • United States
  • Mitsubishi Corporation
  • MAR 02, 2017: INFINITY ANNOUNCES PRESENTATION ON IPI-549 AT AACR ANNUAL MEETING
  • NOV 09, 2016: INFINITY ANNOUNCES SECOND PUBLICATION ON PI3K-GAMMA IN NATURE

April ## - ##.

  • Antimalarials
  • Cancer
  • Therapy
  • United States
  • Product Initiative

The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Antimalarials
  • Asthma
  • World
  • Product Initiative
  • Pharmaxis Ltd
  • NOV 03, 2015: GSK AND MERCK TO STUDY IMMUNOTHERAPY COMBINATION AS POTENTIAL CANCER TREATMENT

OCT ##, 2014: AGONOX' S OX## PLATFORM BEING UTILIZED IN MEDIMMUNE' S PHASE ## OX## AGONIST STUDY AgonOx, a biotechnology company focused on immunotherapy development, announced that its OX## platform is being utilized in MedImmune' s Phase I trial of its humanized OX## a

  • Antimalarials
  • Immunotherapy
  • Monoclonal Antibody
  • Pharmaceutical
  • MedImmune, LLC

Durvalumab acts as PDL-## inhibitor.

  • Antimalarials
  • Oncology
  • United States
  • World
  • Product Initiative
  • MAR 07, 2017: AB SCIENCE ANNOUNCES THAT FRONTIERS IN AGING NEUROSCIENCE PUBLISHES A COMPREHENSIVE REVIEW ON THE FUTURE POTENTIAL OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS

In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy.

  • Antimalarials
  • Clinical Trial
  • Neurology
  • World
  • Product Initiative

(Acquired by Ferring Pharmaceuticals, Inc. ) has signed an exclusive license with Baxter Healthcare Corporation for rights to Cytokine s antimacrophage migration inhibitory factor (MIF) antibody technology.

  • Antimalarials
  • Pharmaceutical
  • United States
  • Product Initiative
  • MediciNova, Inc.

IT IS DEVELOPED BASED ON DUAL SPECIFIC ANTIBODY TECHNOLOGY DIG-BODY.

  • Antimalarials
  • Oncology
  • World
  • Company Operations
  • PharmAbcine, Inc.

(Innate Pharma) is a bio-pharmaceutical company that specializes in the areas of immunopharmacology and antibody technology.

  • Antimalarials
  • Therapy
  • United States
  • World
  • Product Initiative
  • ULTRA-41BBL - DRUG PROFILE

They are in development for immunotherapy of HER##-positive cancers.

  • Antimalarials
  • Immunotherapy
  • Monoclonal Antibody
  • Therapy
  • Pfizer Inc.

The study is open to applicable patients at any line of treatment, before or after treatment with immunotherapies.

  • Antimalarials
  • Targeted Therapy
  • United States
  • Product Initiative
  • AB Science SA
  • Clinical Trial profile. 475 Trial Title
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Antimalarials
  • Clinical Trial
  • Malaria
  • Pharmaceutical
  • World
  • Business description
  • PARTNERSHIP - DEAL REPORTS

(formerly Inovio Biomedical Corporation) is engaged in developing active deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases.

  • Antimalarials
  • Vaccine
  • United States
  • Company
  • Inovio Pharmaceuticals, Inc.